Preclinical evaluation of the PARP-inhibitor olaparib for the treatment of ovarian clear cell cancer

Ovarian clear cell carcinoma (OCCC) is an aggressive histological subtype of epithelial ovarian cancer. De-novo resistance to platinum-based chemotherapy is higher compared to serous ovarian cancers. The aims of this study were to examine the role of a potent poly(ADP) ribose polymerase (PARP)-inhibitor as a potential therapeutic option for OCCCs and if RAD51 foci formation would constitute a surrogate marker for the use of these agents in OCCCs.